Gregory D. Davis's Insider Trades & SAST Disclosures
Gregory D. Davis's most recent trade in Sangamo Therapeutics Inc was a trade of 6,708 Common Stock done at an average price of $0.8 . Disclosure was reported to the exchange on April 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gregory D. Davis.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | Gregory D. Davis | Head of Research & Technology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.78 per share. | 22 Apr 2025 | 6,708 | 209,376 (0%) | 0% | 0.8 | 5,207 | Common Stock |
| Sangamo Therapeutics Inc | Davis D. Gregory | Head of Research & Technology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 99,454 | 99,454 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Gregory D. Davis | Head of Research & Technology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 49,726 | 216,084 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Gregory D. Davis | Head of Research & Technology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.00 per share. | 24 Feb 2025 | 705 | 166,865 (0%) | 0% | 1 | 705 | Common Stock |
| Sangamo Therapeutics Inc | D. Gregory Davis | Head of Research & Technology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.96 per share. | 24 Feb 2025 | 507 | 166,358 (0%) | 0% | 1.0 | 485 | Common Stock |
| Sangamo Therapeutics Inc | Gregory D. Davis | Head of Research & Technology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.15 per share. | 22 Jan 2025 | 30,456 | 167,570 (0%) | 0% | 1.1 | 35,024 | Common Stock |
| Sangamo Therapeutics Inc | Gregory D. Davis | Head of Research & Technology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.88 per share. | 24 Nov 2024 | 721 | 202,368 (0%) | 0% | 1.9 | 1,355 | Common Stock |
| Sangamo Therapeutics Inc | Gregory D. Davis | Head of Research & Technology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.94 per share. | 24 Nov 2024 | 505 | 201,863 (0%) | 0% | 1.9 | 980 | Common Stock |
| Noodles & Company - Ordina... | Scott Gregory Davis | Chief Concept Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2024 | 94,595 | 94,595 (0%) | 0% | 0 | Class A Common Stock | |
| Inotiv Inc | Gregory C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 25,822 | 67,780 (0%) | 0% | 0 | Common Stock | |
| SmartFinancial Inc | Gregory L. Davis | EVP & CHIEF LENDING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 4,321 | 39,852 (0%) | 0% | 0 | Common Stock | |
| Inotiv Inc | Gregory C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 4,275 | 41,958 (0%) | 0% | 0 | Common Stock | |
| Inotiv Inc | Gregory C. Davis | Director | Purchase of securities on an exchange or from another person at price $ 23.93 per share. | 17 Feb 2022 | 2,500 | 36,433 (0%) | 0% | 23.9 | 59,814 | Common Shares |
| Inotiv Inc | Gregory C. Davis | Director | Purchase of securities on an exchange or from another person at price $ 21.12 per share. | 17 Feb 2022 | 1,250 | 37,683 (0%) | 0% | 21.1 | 26,400 | Common Shares |
| Inotiv Inc | Gregory C. Davis | Director | Purchase of securities on an exchange or from another person at price $ 20.57 per share. | 17 Feb 2022 | 1,250 | 33,933 (0%) | 0% | 20.6 | 25,714 | Common Shares |
| SmartFinancial Inc | Gregory L. Davis | EVP & CHIEF LENDING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 2,500 | 35,531 (0%) | 0% | 0 | Common Stock | |
| SmartFinancial Inc | Gregory L. Davis | EVP & CHIEF LENDING OFFICER | Sale or transfer of securities back to the company at price $ 25.06 per share. | 27 Aug 2021 | 3,000 | 33,031 | - | 25.1 | 75,180 | Stock Appreciation Right |
| SmartFinancial Inc | Gregory L. Davis | EVP & CHIEF LENDING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.61 per share. | 27 Aug 2021 | 3,000 | 36,031 | - | 21.6 | 64,830 | Stock Appreciation Right |
| SmartFinancial Inc | Gregory L. Davis | EVP & CHIEF LENDING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2021 | 3,000 | 0 | - | - | Stock Appreciation Right | |
| Inotiv Inc | Gregory C. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 2,683 | 32,683 (0%) | 0% | 0 | Common Shares | |
| SmartFinancial Inc | Gregory L. Davis | EVP & CHIEF LENDING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 2,500 | 33,031 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges